Michael Levy
Prior to this, he was Head of Global Medical Affairs and Medical Director for Europe/Canada for Bayer Pharmaceuticals since 2010.
Before joining Bayer, Dr Levy was CEO and Founder of Cerulean Bioscience, a privately-held biotechnology company in San Francisco, CA. Previously he was Executive VP of R&D at Nuvelo Inc., a publicly-traded biotech company in San Carlos, CA from 2004 to 2008.
Levy came to Nuvelo from Tularik Inc., a publicly-traded biotechnology company in South San Francisco, CA (acquired by Amgen Inc. in 2004) where he served as Vice President of Development and Chief Medical Officer from 2000 to 2004.
Prior to joining Tularik, Dr Levy spent 12 years at GlaxoSmithKline Inc. in Canada, where he held several positions including his final role as Senior Vice President of R&D and Chief Medical Officer.
Dr Levy earned his BA, MA and medical degrees at Cambridge University, UK He undertook his surgical residency at the Mayo Clinic and received the distinction of being elected, a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.
Articles: Michael Levy
Curing the Incurable: Cell & Gene Therapy and A New Age for Pharmacovigilance
Global / Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on pharmacovigilance and patient safety. Levy examines why these potentially revolutionary new therapies will necessitate a rethinking and adaptation of currently existing pharmacovigilance processes and activities. While traditional medicines have, without a doubt, improved the lives of…
Pharmacovigilance: Steadying the Ship Through the COVID-19 Storm
Opinion / Michael Levy, head of pharmacovigilance at Bayer Pharma and Bayer Consumer Health, makes a compelling case for the critical role of pharmacovigilance in ensuring ensuring patient safety and future-proofing the global pharma industry amidst the rush to develop and repurpose treatments and vaccines for COVID-19. The COVID-19 virus overtook the world this year,…
How AI is Transforming Pharmacovigilance
Opinion / Bayer’s Michael Levy examines how artificial intelligence (AI) can assist in both the routine and advanced analytical tasks involved in conducting pharmacovigilance and therefore better ensure the safety of pharmaceuticals and the health of patients. Pharmacovigilance or Patient Safety aims to promote and protect the health and well-being of patients and other healthcare consumers.…
Latest Report
